Hikma Expectations Stabilize – But Generics Still Set To Take A Hit

After issuing two downgrades in guidance for its Generics business across the previous two quarters, Hikma has used its latest trading update to confirm that no further cuts to Generics guidance are expected this year, while the company’s Injectables and Branded segments are enjoying “strong momentum.”

Having started the year by warning of pressures to come on US generics (Also see "Hikma Warns Of Renewed Pricing Pressure On US Generics" - Generics Bulletin, 3 March, 2022.), Hikma had nevertheless initially suggested that a slow start for the Generics unit in 2022 would later pick up, with revenues more weighted towards the end of the year, resulting in overall growth of 8%-10% over 2021’s figure of $820m